» Articles » PMID: 39839605

Protocol for a Prospective Observational Cohort Study of Cutaneous Leishmaniasis in Ethiopia

Abstract

Background: Cutaneous leishmaniasis (CL) is a skin neglected tropical disease, with an estimated 40,000 new cases each year in Ethiopia. CL causes ulcers, nodules, and plaques on the skin, and in some instances the destruction of the nasopharyngeal mucosa and cartilage. Some CL lesions may heal spontaneously, whilst other lesions may require therapies which are associated with discomfort, adverse effects, prolonged treatment, and a frequent lack of a complete response. Scarring, a sequela of CL, causes permanent disfigurement and is associated with stigma linked with a reduction in health-related quality of life.The choice of treatment for CL is based upon factors including the causative species; the number, extent, size, and location of lesions; and the availability of treatments. The development of robust evidence for CL treatment is hindered by a lack of validated and appropriate outcome measures and few data to support hypothesis-generation and trial design. There is a paucity of prospective data with well-defined treatment outcomes for CL caused by .

Aim: The overall aim of this study is to improve the understanding of the health and economic burden of CL.

Methods: We have designed an observational, multi-centre cohort study to examine treatment outcomes for CL in Ethiopia which includes clinical outcomes, laboratory outcomes, patient reported outcome measures, scar assessments and cost effectiveness. We aim to recruit up to 750 participants across two hospital sites. We present here the protocol for this cohort study with a 12-month follow up period for each participant.

Conclusions: These data will inform the design of randomized controlled trials to evaluate new treatment strategies, with appropriate economic evaluations. This will help improve evidence-based guidelines and support evidence-led policy decisions, not only in Ethiopia but also globally.

Citing Articles

Effectiveness of carbon dioxide cryotherapy for the treatment of cutaneous leishmaniasis: Systematic review and meta-analysis.

Tilahun Zewdu F, Misganaw Geremew B, Gadisa Belachew E, Alemu Gelay K PLoS Negl Trop Dis. 2025; 19(1):e0012741.

PMID: 39761302 PMC: 11771858. DOI: 10.1371/journal.pntd.0012741.

References
1.
Fikre H, Mohammed R, Atinafu S, van Griensven J, Diro E . Clinical features and treatment response of cutaneous leishmaniasis in North-West Ethiopia. Trop Med Int Health. 2017; 22(10):1293-1301. DOI: 10.1111/tmi.12928. View

2.
Akuffo H, Dietz M, Teklemariam S, Tadesse T, Amare G, Berhan T . The use of itraconazole in the treatment of leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg. 1990; 84(4):532-4. DOI: 10.1016/0035-9203(90)90028-d. View

3.
Reithinger R, Coleman P . Treating cutaneous leishmaniasis patients in Kabul, Afghanistan: cost-effectiveness of an operational program in a complex emergency setting. BMC Infect Dis. 2007; 7:3. PMC: 1790896. DOI: 10.1186/1471-2334-7-3. View

4.
Refai W, Madarasingha N, Sumanasena B, Weerasingha S, De Silva A, Fernandopulle R . Efficacy, Safety and Cost-Effectiveness of Thermotherapy in the Treatment of Induced Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial. Am J Trop Med Hyg. 2017; 97(4):1120-1126. PMC: 5637590. DOI: 10.4269/ajtmh.16-0879. View

5.
Olliaro P, Grogl M, Boni M, Carvalho E, Chebli H, Cisse M . Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation. PLoS Negl Trop Dis. 2018; 12(1):e0006141. PMC: 5785032. DOI: 10.1371/journal.pntd.0006141. View